14-Aug-2025 7:00 AM CST - Business Wire Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. CEO Commentary The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with
14-May-2025 3:15 PM CST - Business Wire Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025. The first quarter of 2025 was highlighted by continued progress in the development of EB-003, our neuroplastogenic
31-Mar-2025 7:00 AM CST - Business Wire Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported financial results for the fourth quarter and year ended December 31, 2024. Enveric is entering 2025 with a clear miss
14-Nov-2024 3:05 PM CST - Business Wire Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge
14-Aug-2025 7:00 AM CST - Business Wire Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. CEO Commentary The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with
14-May-2025 3:15 PM CST - Business Wire Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025. The first quarter of 2025 was highlighted by continued progress in the development of EB-003, our neuroplastogenic
31-Mar-2025 7:00 AM CST - Business Wire Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported financial results for the fourth quarter and year ended December 31, 2024. Enveric is entering 2025 with a clear miss
14-Nov-2024 3:05 PM CST - Business Wire Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge
